By partnering with an established force in the Chinese genomics market Cogenics is hoping to gain access to clients beyond its primary markets in the US and Europe.
SinoGenoMax provides genomic services to local and international universities, research institutes and pharmaceutical companies. The partnership should give Cogenics access to these clients and expand the range of services that the companies can offer.
Michael Lutz, Global Manager of Cogenics, said: “The extensive pharmaceutical and biotechnology infrastructure and large number of clinical trials conducted in China make this an increasingly important market for clinical genotyping services.
“Our partnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with similar platforms and high quality standards, thus expanding Cogenics’ offering to our growing global pharmaceutical customer base.”
Cogenics claims its clients include the top 20 pharmaceutical companies operating in the US and Europe. Companies in China will now have greater access to these services, which include next generation sequencing, gene expression and clinical and non-clinical genotyping.
In addition Cogenics can provide biomanufacturing support, nucleic acid extraction and biobanking for research and regulated environments.
Cogenics entry into China suggests it believes that the number of clinical trials conducted in the country will continue to grow, driving demand for related services.